Alere Inc. (ALR)
(Delayed Data from NYSE)
$50.99 USD
0.00 (0.00%)
Updated Oct 2, 2017 04:02 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ALR]
Reports for Purchase
Showing records 1 - 20 ( 92 total )
Industry: Medical - Products
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Industry: Medical - Products
Updating Model Post BBI Divestiture - Tweaking Estimates Lower - Still Confused by Magnitude of 3Q15 Q/Q Infectious Disease Decline - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
Global Complexities Drive 3Q15 Miss - Guidance Reset - Not Overly Worried But We Question the Growth Story - Lowering PT to $39 - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
3Q15 Preview - Expecting In-line Sales - Better EPS - Checks Suggest Intact Professional Dx Share - Our Focus is on FCF - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
2Q15 Topline Beat Driven By Better Infectious Disease Growth - Upping Estimates - Still Sticklers for FCF - Maintain NEUTRAL - PT to $43
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
Thoughts Post AACC Meeting - 2Q15 Preview - Expecting Slightly Lower Results - Near Term Alere I Story Sounding Solid - Maintaining NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
1Q15 Recap - Revenue A Tad Soft - EPS Solid - Solid GMs - Opex - Alere I - Epocal Sounding Better - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
Investor Day Recap - Near-Term Product Roadmaps - Leverage Story in Line - Revenue Guidance a Little Low - Alere I Traction Seems Better - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
4Q14 Recap - Good Opex Discipline - Rationalizations Offset Weaker Top Line - GMs
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Expecting 4Q14 Results to Top True Consensus Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
3Q14 Recap - Much-Needed Divestiture & Massive Cost Cutting Offset Weak Top line
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
3Q14 Preview - Expecting Better Top-line & Lower EPS - Disease Activity Looking Better
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
2Q14 Sales Edge Above our Street-Low View - EPS & GMs Miss
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
2Q14 Sales Look Like a Bit of a Stretch - More Optimism on EPS
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
1Q14 Top-line Misses - Weaker Flu & Hospital Visits Impact Sales - Still Skeptical of the 2H14 Growth Story - Opex & Taxes Looking Better - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Products
Industry: Medical - Products
4Q13 EPS Beat Driven By Royalties & Flu - Tox & Cardio Sales Softer - Emerging Markets Solid - Rev Acceleration Story Not Yet Convincing - Reaffirm N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z